SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

VOLUNTARY ANNOUNCEMENT
H1710 INJECTION RECEIVED THE NOTICE OF APPROVAL FOR CLINICAL TRIAL FROM NMPA

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has recently received the Notice of Approval for Clinical Trial (《藥物臨床試驗批准通知書》) issued by the National Medical Products Administration ("**NMPA**") for approving the H1710 injection ("**H1710**"). Relevant information is as follows:

DETAILS ABOUT H1710

Drug Name	:	H1710 injection
Indications	:	Advanced solid tumor
Registration Classification	:	Class 1 chemical drug
Application Matter	:	Clinical trial
Applicant	:	Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Review Conclusions	:	According to the Drug Administration Law of the People's Republic of China (《中華人民共和國藥品管理法》) and relevant regulations, upon review, the investigational new drug application for the H1710 injection accepted on December 3, 2024 meets the relevant requirements for drug registration, and this drug has been approved to conduct clinical trials as monotherapy for the treatment of advanced solid tumors

H1710 is a candidate drug independently developed by the Company, and the Company owns the global rights to develop and commercialize H1710. H1710 is a novel compound that targets heparanase, a heparin-degrading enzyme. It has a suitable chain length and a unique flexible structure, and competitively binds to heparanase with heparan sulfate proteoglycans or heparin, making it a highly efficient and selective heparanase inhibitor. Heparanase is overexpressed in various tumors and is associated with tumor growth and metastasis. Studies have shown that targeting heparanase is a new anticancer strategy. The Company's preclinical research has demonstrated that H1710 exhibits anti-tumor pharmacological activity by inhibiting the activity and expression of heparanase. H1710 has shown significant anti-tumor effects in various tumor animal models. As at the date of this announcement, there is no similar product with the same molecular mechanism on the market worldwide.

RISK WARNING

According to the relevant laws and regulations related to national drug registration, drugs are required to conduct clinical trials and obtain relevant data after receiving the Notice of Approval for Clinical Trial, and can only be marketed after being approved by the NMPA.

Since clinical research involves a long cycle, high investment and many unpredictable factors during the process, there are many uncertainties regarding the results and time of clinical trials, review and approval. The Company will fulfill its information disclosure obligations in a timely manner for subsequent development progress. **Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

Announcement is hereby given.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
February 18, 2025

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.